{"id":"tap-144-sr-6m","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"5-15","effect":"Injection site reaction"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"30-50","effect":"Erectile dysfunction"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":null,"effect":"Bone density loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Leuprolide works by binding to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH (flare effect) followed by sustained suppression of these hormones. This leads to castration-level testosterone suppression in males and estrogen suppression in females. The SR(6M) designation indicates a 6-month sustained-release depot formulation designed for prolonged hormone suppression with less frequent dosing.","oneSentence":"TAP-144-SR is a sustained-release formulation of leuprolide, a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone to reduce sex hormone production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:52.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT01546649","phase":"PHASE3","title":"A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-04","conditions":"Premenopausal Breast Cancer","enrollment":167},{"nctId":"NCT01546623","phase":"PHASE3","title":"A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-03","conditions":"Prostate Cancer","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAP-144-SR(6M)","genericName":"TAP-144-SR(6M)","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAP-144-SR(6M) is a small molecule being studied in clinical trials for the treatment of premenopausal breast cancer and prostate cancer. It is being compared to another formulation, TAP-144-SR(3M), in a Phase 3 clinical trial.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}